Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Centers for Disease Control and Prevention University of Texas Columbia University University of KwaZulu University of Cape Town Boston University Pfizer |
---|---|
Information provided by: | Centers for Disease Control and Prevention |
ClinicalTrials.gov Identifier: | NCT00691392 |
This is a one-period, double-blind, single-center pharmacokinetic study of linezolid in patients with MDR or XDR tuberculosis treated with linezolid and an Optimized Background Therapy (defined as treatment with > 4 drugs with activity against tuberculosis to which the patient's isolate is believed to be sensitive by history or based on drug sensitivity testing).
Condition | Intervention | Phase |
---|---|---|
Multi-Drug Resistant Tuberculosis Extensively Drug Resistant Tuberculosis |
Drug: Linezolid Drug: Microcrystalline Methylcellulose - Placebo |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis |
Estimated Enrollment: | 50 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | October 2010 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Linezolid 600 mg po daily for 16 weeks (112 doses) given in addition to optimized background therapy for MDR TB
|
Drug: Linezolid
Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated
|
2: Placebo Comparator
Over-encapsulated microcrystalline methylcellulose (Avicel) - an inert filler
|
Drug: Microcrystalline Methylcellulose - Placebo
The placebo will be over-encapsulated microcrystalline methylcellulose
|
This is a one-period, double-blind, single-center pharmacokinetic study of linezolid in patients with MDR or XDR tuberculosis treated with linezolid and an Optimized Background Therapy (defined as treatment with > 4 drugs with activity against tuberculosis to which the patient's isolate is believed to be sensitive by history or based on drug sensitivity testing).
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Nesri Padayatchi, MBChB | 27-31-260-4574 | padayatchin@ukzn.ac.za |
Contact: Nelisiwe Mnguni, RN | 27-83-465-8785 | mngunin3@ukzn.ac.za |
South Africa, KwaZulu Natal | |
King George V Hospital | |
Durban, KwaZulu Natal, South Africa |
Principal Investigator: | Nesri Padayatchi, MBChB | University of KwaZulu |
Principal Investigator: | Marc Weiner, MD | University of Texas |
Responsible Party: | Centers for Disease Control and Prevention ( William R. Mac Kenzie MD/Project Officer ) |
Study ID Numbers: | TBTC Study 30PK |
Study First Received: | June 3, 2008 |
Last Updated: | June 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00691392 |
Health Authority: | United States: Food and Drug Administration; South Africa: Medicines Control Council |
Multi-Drug Resistant Tuberculosis Extensively Drug Resistant Tuberculosis MDR TB |
XDR TB MDR XDR |
Bacterial Infections Gram-Positive Bacterial Infections Tuberculosis, Multidrug-Resistant Mycobacterium Infections |
Extensively Drug-Resistant Tuberculosis Tuberculosis Linezolid |
Protein Synthesis Inhibitors Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Enzyme Inhibitors Pharmacologic Actions Actinomycetales Infections |